title: Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
abstract: BACKGROUND
  Beyond the usual regimens based on streptozocin and doxorubicin or 5-fluorouracil, no second-line therapy of metastatic neuroendocrine tumor has gained wide acceptance. Gemcitabine and oxaliplatin are generally well tolerated and have shown activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine-oxaliplatin combination (GEMOX) in the treatment of patients with metastatic neuroendocrine tumors.
  
  
  METHODS
  Twenty consecutive patients with progressive disease were treated with GEMOX, in most cases after failure of other chemotherapy regimens (median=2). Patients were followed for evidence of toxicity, response, and survival. Two patients were chemotherapy-naive at treatment initiation and were excluded from the efficacy analysis.
  
  
  RESULTS
  Toxicity was manageable overall; however, 6 (30%) patients had to discontinue treatment because of oxaliplatin-induced neurotoxicity (grade 2). Three (17%) of 18 patients had a partial response, median progression-free survival was 7.0 months, and median overall survival was 23.4 months.
  
  
  CONCLUSIONS
  Gemcitabine-oxaliplatin combination shows interesting activity and is well tolerated in pretreated patients with neuroendocrine tumors.
authors.affiliation: Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
authors.forename: Philippe A
authors.initials: PA
authors.lastname: Cassier
authors.forename: Thomas
authors.initials: T
authors.lastname: Walter
authors.forename: Beatrice
authors.initials: B
authors.lastname: Eymard
authors.forename: Philippe
authors.initials: P
authors.lastname: Ardisson
authors.forename: Maurice
authors.initials: M
authors.lastname: Perol
authors.forename: Carole
authors.initials: C
authors.lastname: Paillet
authors.forename: Jean-Alain
authors.initials: JA
authors.lastname: Chayvialle
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Valerie
authors.initials: V
authors.lastname: Hervieu
authors.forename: Catherine Lombard
authors.initials: CL
authors.lastname: Bohas
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000556:secondary*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D019233:Retreatment; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine